Highlights of the Study
• Intravoxel Incoherent Motion is a diffusion imaging method which is being used clinically for the evaluation of tissue perfusion without the use of contrast media.
• The f (perfusion fraction) value of Intravoxel Incoherent Motion may quantitatively reflect the response of antiangiogenic therapy.
• Intravoxel Incoherent Motion could be added in routine protocols for Magnetic Resonance Imaging to assess response of tumours to antiangiogenic agents.
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Introduction
Colorectal carcinoma (CRC) is the second most common cause of cancer death, and its most frequent distant metastatic target organ is the liver. The treatment of metastatic CRC (mCRC) has improved in the last 20 years. Thirion et al. [1] have reported that the addition of leucovorin to 5-fluorouracil (5-FU) increased overall survival to 12 months in mCRC patients.
This protocol and its combinations have become the cornerstones for development of new protocols for such patients [1] . Oxaliplatin and irinotecan combinations, known as FOLFOX and FOLFIRI protocols, improved the overall survival to 16 -18 months. Moreover, targeted antiangiogenic agents have been added to these basic cornerstone protocols, increasing the survival by up to 24 -30 months [2] . Bevacizumab, widely used for mCRC treatment, is a targeted antiangiogenic agent; it is an antibody to vascular endothelial growth factor (VEGF).
Its multiple mechanisms of action result in the inhibition of new vessel growth [3] .
The response of mCRC patients to treatment can be evaluated by patient's physical examination, carcinoembryonic antigen (CEA) levels if initially elevated, and various imaging techniques. Non-invasive imaging techniques play an important role to evaluate tumour responses during antiangiogenic therapies [4] .
As antiangiogenic therapy mainly acts on the tumour vasculature, change in tumour size requires a long time. Therefore, biomarkers other than size are needed to assess the early response to therapy. The response to antiangiogenic therapy has been assessed with the use of contrast-enhanced imaging techniques both on CT and MRI [5] . A c c e p t e d m a n u s c r i p t diagnostic tool for the evaluation of liver lesions and parenchymal changes [7] . DWI reflects the water proton mobility in a voxel and provides information about cell microstructure, microcirculation, cell membrane integrity and cell viability [3, 7] . DWI measures the random motion of water molecules in the tumour. When the motion of water molecules is restricted due to high cellularity in the environment, their diffusion is also restricted. After the treatment, the cellularity of the tumour decreases and in some cases necrosis occurs; these changes bring about an increase in the free motion of water molecules and an increase in their diffusion. DWI and apparent diffusion coefficient (ADC) maps are also affected by tissue perfusion of the microvascular capillary [8] . The Intravoxel Incoherent Motion (IVIM) theory of Le Bihan et al. [9] states that increasing the number of b-values leads to a multi-exponential signal drop within each voxel and enables quantitative parameters that measures tissue microcapillary perfusion. This helps to differentiate between true molecular diffusion and microcapillary perfusion [9] , and thus is helpful for the diagnosis and the follow-up of the hypervascular lesions. As tumour perfusion changes after antiangiogenic treatments, low and high b-values reflect the changes in microcapillary tissue perfusion and also diffusivity without the need of contrast agent use. The perfusion-sensitive parameters perfusion fraction (f) and pseudodiffusion coefficient (D*), and the diffusion-sensitive parameter, true diffusion coefficient (D) can be measured and mapped separately with biexponential analysis [10] . The perfusion parameters are also obtained by signal intensity (SI) curve biexponential analysis with increasing b-values by the same technique [8] .
Bevacizumab therapy is widely used for brain gliomas, kidney, lung, colon, rectum, cervix, ovary and fallopian tube cancers. Recent studies also investigated the changes of IVIM parameters and tumor response in non-small cell lung cancer and gliomas [11, 12] . The value of IVIM for the assessment of the effectiveness of the early treatment has been published in a few reports. In this pilot study, which, to the best of our knowledge is the first, we aimed to 
Subjects and Methods
This study was carried out between March 2016 and August 2018. informed consent before they were included in the study.
Patients
12 patients diagnosed as unresectable CRC with 25 liver metastases were enrolled in the study. Three patients (seven metastases) with poor diagnostic imaging quality due to motion artefacts were excluded from the study. One patient (two metastases) was lost to follow-up.
Finally, eight patients (three females and five males) with a total of 16 metastases were included in this study. The mean age was 60 years, range between 41 -73 years. All patients were treated for a total of nine months by FOLFOX or FOLFIRI protocols combined with bevacizumab therapy.
MR Imaging
All patients were underwent MRI before the treatment and then on the 3rd, 6th and 9th months after the start of the therapy. All MR images were obtained in a Siemens, Magnetom D, D* and f values were postprocessed using a free specific software prograe from the website http://yamarad.umin.ne.jp/ivim/simplex_en.html [14] .
Statistical Evaluation
The lesions were compared to assess the effect of the IVIM parameters at PT, 3 rd , 6 th and 9 th months of the therapy were compared to determine how these parameters change during the antiangiogenic therapy. The goodness of fit of the data to a normal distribution was identified by the Kolmogorov-Smirnov test. The differences in the IVIM parameters and changes in these parameters during the therapy were determined by independent samples t test.
All of the statistical evaluations were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA) statistical software.
Results
Of the 8 patients with 16 liver metastases included in the study, four patients had SD (2 adenocarcinoma lesion, 2 musinous carcinoma lesion), 3 had PR (11 adenocarcinoma lesion, 2 musinous carcinoma lesion), and 1 had PD (1 musinous carcinoma lesion) according to the RECIST 1.1 criteria [13] . Five patients were male, and the mean age was 60 years (range 41-73 years). Thirteen lesion were adenocarcinoma metastases (11 lesions, 3 lesions were musinous carcinoma metastases.
Results of the quantitative analysis of IVIM parameters and comparison of PT values
with post-treatment values after 3, 6 and 9 months are presented in the Table 1 and Figure 2a .
The diameters of the metastases were statistically significant diminished at 9 th month when compared with PT (p = 0.03). Conventional ADC and D values of the metastases increased at the 9 th month compared with the PT values (p = 0.10, and p = 0.21, respectively). D* value was the highest at 3 rd month (p = 0.24), and a decrease was found at 6 th , and 9 th months of therapy (p = 0.97, and p = 0.87, respectively). The f value had the highest peak at 3 rd month (p = 0.51), started to decrease after 3 rd month. At the 6 th month f decreased to lowest values (p = 0.12) ( Figure 2b ). SI measurements were lowest on the 6 th month of therapy. IVIM parameter trends for the different disease response groups are summarized in the Table 2 .
Discussion
The results of this initial data showed the role of functional IVIM in the assessment of antiangiogenic therapy response without using intravenous contrast agent.
Most studies evaluating the short-term effects of antiangiogenic therapy have shown that successful treatment is reflected by an increase in tumour ADC values [3] . Cui et al.
reported that ADC values of responder liver metastases increases after one week of chemotherapy [15] . Significant ADC elevation in responding metastases after long-term Disclosure Statement: All authors declare that they have no conflicts of interest.
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